- Home
- ARCT vs STOK Comparison
ARCT vs STOK Comparison
Compare ARCT & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- STOK
- Stock Information
- Founded
- ARCT 2013
- STOK 2014
- Country
- ARCT United States
- STOK United States
- Employees
- ARCT N/A
- STOK N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- STOK Health Care
- Exchange
- ARCT Nasdaq
- STOK Nasdaq
- Market Cap
- ARCT 444.5M
- STOK 408.8M
- IPO Year
- ARCT N/A
- STOK 2019
- Fundamental
- Price
- ARCT $13.08
- STOK $9.67
- Analyst Decision
- ARCT Strong Buy
- STOK Strong Buy
- Analyst Count
- ARCT 7
- STOK 6
- Target Price
- ARCT $57.80
- STOK $26.00
- AVG Volume (30 Days)
- ARCT 451.8K
- STOK 992.3K
- Earning Date
- ARCT 05-07-2025
- STOK 05-05-2025
- Dividend Yield
- ARCT N/A
- STOK N/A
- EPS Growth
- ARCT N/A
- STOK N/A
- EPS
- ARCT N/A
- STOK N/A
- Revenue
- ARCT $152,310,000.00
- STOK $36,555,000.00
- Revenue This Year
- ARCT N/A
- STOK $27.80
- Revenue Next Year
- ARCT $39.21
- STOK $9.53
- P/E Ratio
- ARCT N/A
- STOK N/A
- Revenue Growth
- ARCT N/A
- STOK 316.34
- 52 Week Low
- ARCT $8.04
- STOK $5.35
- 52 Week High
- ARCT $45.00
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- ARCT 60.60
- STOK 69.88
- Support Level
- ARCT $10.07
- STOK $7.31
- Resistance Level
- ARCT $11.00
- STOK $7.99
- Average True Range (ATR)
- ARCT 0.89
- STOK 0.68
- MACD
- ARCT 0.53
- STOK 0.41
- Stochastic Oscillator
- ARCT 100.00
- STOK 99.31
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.